Home » Race against the mutant strain Kexing will submit an application for emergency use of the delta strain vaccine-IT & Health

Race against the mutant strain Kexing will submit an application for emergency use of the delta strain vaccine-IT & Health

by admin

Since the emergence of the new coronavirus delta variant (Delta) in India in 2020, it has now spread to more than 130 countries and regions around the world. All parties are working hard on this variant with high viral load, short incubation period, and rapid spread. Promote vaccine research and development. On August 5, Kangtai Bio (300601.SZ) announced that the company has made important progress in its vaccine research and development project for the new coronavirus variant, and it has successfully isolated multiple monoclonal strains of the delta variant.

The two new crown inactivated vaccine companies that were the first to enter the conditional listing in China, Kexing and Zhongsheng have also carried out vaccine research and development on delta variants.

“Kexing will also submit clinical research and emergency use applications for the Gamma strain of Kellyford and Delta strain of Kellyford to the national drug administrations in the near future.” August 5, Director of Kexing Holding Biotechnology Co., Ltd. Chang Yin Weidong revealed to China Business News.

The Zhongsheng Group is also promoting the research and development of inactivated vaccines against multiple mutant strains. It is reported that Zhongsheng is currently in the process of developing an inactivated vaccine against beta variants, and is currently in the stage of animal experiments. Inactivated vaccines against delta variants are also under development. In other technical routes, the research and development of recombinant protein vaccines and mRNA vaccines against variant strains are also in progress.

“For the inactivated vaccine of the delta variant strain, we have recently submitted a (clinical research) application.” Zhang Yuntao, vice president of China National Biotechnology Co., Ltd., told CBN.

See also  Buick GL8's ultimate rival appeared in Guangzhou Automobile Toyota SIENNA real car debut-IT and traffic

At present, the delta variant is the main strain in the global new crown pneumonia epidemic, and it is also the culprit of the current Nanjing epidemic and the Zhengzhou epidemic.

At a press conference on the Joint Prevention and Control Mechanism of the State Council on August 5, He Qinghua, the first-level inspector of the CDC of the National Health Commission, said that the Delta variant was first discovered in the new coronary pneumonia cases reported in India in September 2020. The Health Organization announced on May 10 this year that the delta variant will be included in the new coronavirus variant of global concern. At present, it has been circulating in more than 130 countries and regions and has become the main virus strain of the global new crown pandemic. This strain has the characteristics of fast transmission, fast replication in the body, and long time to turn negative.

However, He Qinghua also stated that relevant scientific research and epidemic prevention and control practices at home and abroad have shown that the Delta mutant strain has not caused a subversive change in the biological characteristics of the new crown virus. The source of infection and the route of transmission are basically clear. The existing epidemic prevention and control measures are effective. The delta variant is still effective. Existing vaccines still have good preventive and protective effects, can reduce the risk of virus transmission in the population, reduce the transmission power of infected persons, and effectively reduce the incidence of severe illness and mortality after infection.

See also  SENA launched its Technopark in Arauca – news

According to some research data, the current inactivated vaccine for the new crown is still effective against the delta mutant strain.

On July 20, a research institute in Sri Lanka released a real-world protection research report on the effectiveness of China’s biological new crown vaccine, which showed that the vaccine has antibody levels and natural infections against the currently circulating variants of Delta and Beta strains. After the formation of immunity, the level is similar. Compared with the early Chinese new coronavirus strains, the Chinese biological new crown inactivated vaccine has an antibody neutralization activity against the currently discovered delta mutant strains. In other words, after being immunized with two injections of the inactivated vaccine of China Biology, there is still a 68% protection rate against the currently circulating delta mutant strain. China’s biological new crown vaccine still has a good protective effect against the Delta strain.

However, it cannot be ignored that the delta variant has also caused breakthrough infection cases in many countries.

On July 30, local time, the CDC (U.S. Centers for Disease Control and Prevention) issued the “Morbidity and Mortality Weekly Report (MMWR)”, stating that Delta virus infection caused the same high levels of new coronavirus among vaccinated and unvaccinated people. Capacity. A high viral load indicates an increased risk of transmission and raises concerns that, unlike other variants, vaccinated persons infected with delta virus can transmit the virus. The study found that 274 (79%) vaccinated patients with breakthrough infection developed symptoms.

Because of this, racing against mutant strains has also become the main task of vaccine research and development.

See also  Serie A: Empoli-Juventus 4-1, the bianconeri now out of Europe - Tuscany

According to news from Kexing, Kexing Zhongwei isolated the Gamma mutant strain in December 2020, and the delta mutant strain in April, and invested in research on the new crown inactivated vaccine strain replacement operation.

“Actually, the research work on replacing the inactivated vaccine strain has been ongoing, but in the first half of the year, because it was not clear which will become the main epidemic strain, there was no rush to replace the inactivated vaccine strain. The work of changing virus strains can only be carried out after judging the trend of circulating virus strains. However, because the preliminary work is sufficient, once the mainstream virus strains are found, they can be replaced at any time.” An epidemiologist said.

According to Yin Weidong, Kexing Zhongwei has sufficient production capacity to provide different types of inactivated COVID-19 vaccines.

.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy